Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.04 USD | -5.82% | -7.80% | +46.31% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 13.19M | Capitalization | 1.6B |
---|---|---|---|---|---|
Net income 2024 * | -194M | Net income 2025 * | -216M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 121 x |
P/E ratio 2024 * |
-9.07
x | P/E ratio 2025 * |
-8.73
x | Employees | 142 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.37% |
Latest transcript on Kura Oncology, Inc.
1 day | -5.82% | ||
1 week | -10.58% | ||
Current month | -0.19% | ||
1 month | +2.04% | ||
3 months | +71.06% | ||
6 months | +112.74% | ||
Current year | +46.31% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
CEO | Chief Executive Officer | 55 | 14-08-21 |
Stephen Dale
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-08-24 |
Kathleen Ford
COO | Chief Operating Officer | 77 | 19-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 21-06-02 |
Faheem Hasnain
BRD | Director/Board Member | 65 | 15-04-26 |
Thomas Malley
BRD | Director/Board Member | 55 | 15-10-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 21.04 | -5.82% | 1,014,156 |
24-03-15 | 22.34 | +1.64% | 3,345,487 |
24-03-14 | 21.98 | -3.72% | 1,170,025 |
24-03-13 | 22.83 | +2.33% | 685,927 |
24-03-12 | 22.31 | -2.23% | 1,144,747 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+46.31% | 1.7B | |
+1.10% | 105B | |
+9.29% | 104B | |
-3.00% | 22.09B | |
-11.89% | 21.98B | |
-26.59% | 20.17B | |
-5.20% | 19.49B | |
-6.58% | 17.75B | |
+5.83% | 13.84B | |
+7.46% | 11.64B |